Body composition alteration and inflammation are independent predictors of survival in lung cancer patients treated with anlotinib. (December 2020) - Pan, Q.; Zheng, H.; Zhu, W.; Niu, Z.; Li, H.; Fang, Y.; Zheng, Y.; Li, D.; Lou, H.; Hu, H.; Zhai, C.; Wang, W.; et al.